神经内分泌瘤中的治疗疗效
Nadine Mallak1, Sophia R O'Brien2, Daniel A Pryma2
1From the Department of Diagnostic Radiology, Oregon Health & Sciences University, Portland, OR.
Cancer journal (Sudbury, Mass.)
|May 16, 2024
概括
本综述探讨了针对体静止素受体 (SSTR) 的成像和治疗神经内分泌瘤 (NETs) 的进展. 它还讨论了针对色红细胞瘤/帕拉格林瘤 (PPGLs) 的向性治疗,并指出了近期治疗可用性的变化.
科学领域:
- 在瘤学瘤学.
- 核医学就是核医学.
- 放射性药理学 是一种放射性药理学.
背景情况:
- 神经内分泌瘤 (NETs) 和肌染色细胞瘤/副细胞瘤 (PPGLs) 是源自神经内分泌细胞的罕见瘤.
- 胃肠道胰腺 NET 经常过度表达体静止素受体 (SSTR),而 PPGL 则通常过度表达北上腺素载体.
- 最近的进展对这些罕见瘤的诊断和治疗策略产生了重大影响.
研究的目的:
- 提供当前针对NET的SSTR向成像和治疗的全面审查.
- 讨论针对PPGLs的诺亚上腺素载体向治疗的作用和结果.
- 探讨NET和PPGL治疗术的不断变化的前景,包括最近治疗可用性的变化.
主要方法:
- 食品和药物管理局批准的SSTR-agonist正子发射断层扫描追踪器的审查.
- 对SSTR向治疗的预测成像生物标志物的分析.
- 讨论177Lu-DOTATATE受体放射性核酸治疗,包括重新治疗和治疗后成像.
- 检查131I-metaiodobenzylguanidine (mIBG) 对于PPGLs的治疗药物及其商业不可用性的影响.
主要成果:
- 针对SSTR的成像和治疗已经彻底改变了NET管理.
- 177Lu-DOTATATE为NET提供了一个重要的治疗选择,在再处理和成像方面不断发展的实践.
- 用131I-mIBG针对诺亚上腺素载体的治疗已经显示出对PPGL的最佳结果,尽管它的可用性现在有限.
- 目前正在探索SSTR疗法作为PPGL的替代品.
结论:
- 针对SSTR的天文学是现代NET管理的基石.
- 虽然131I-mIBG是PPGLs的关键疗法,但其不可用性需要探索SSTR治疗术等替代策略.
- 对于改善NET和PPGL患者的治疗结果,持续研究和开发诺斯学方法至关重要.
更多相关视频
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
17.6K
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
1.9K
相关概念视频
02:49Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820